Evidence map›Paper›PMID 35468623›Full record

ArticleBlood advances2022

Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT.

Mouhamed Yazan Abou-Ismail, Adam J Kanack, Noah P Splinter, Kristi J Smock, Karen A Moser, Anand Padmanabhan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Vaccine-induced immune thrombotic thrombocytopenia.Best practice & research. Clinical haematology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mouhamed Yazan Abou-IsmailDivision of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, UT.ORCID 0000-0002-6682-4366
Adam J KanackDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Noah P SplinterDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Kristi J SmockDepartment of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT.ORCID 0000-0003-0304-6461
Karen A MoserDepartment of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT.ORCID 0000-0002-2258-4444
Anand PadmanabhanDivisions of Hematopathology, Transfusion Medicine, & Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-2519-4377

Funding

New approaches to the pathophysiology, diagnosis and management of heparin-induced thrombocytopeniaR01HL158932 · NHLBI · MAYO CLINIC ROCHESTER · PI PADMANABHAN, ANAND · 2021 to 2025
$2.0M
NHLBI NIH HHS R01 HL158932
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Ad26COVS1BNT162 VaccineCOVID-19ThrombocytopeniaThrombosisHumansAd26COVS1BNT162 Vaccine

Identifiers

PMID35468623
PMCPMC9631692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.